Philip morris international announces closing of fertin pharma acquisition; advances pmi's goal of becoming a majority smoke-free business by 2025 and creates growth opportunities beyond nicotine

New york--(business wire)--regulatory news: philip morris international inc. (pmi) (nyse: pm) today announced the closing of its acquisition of fertin pharma a/s (“fertin pharma”), a leading developer and manufacturer of innovative pharmaceutical and well-being products based on oral and intra-oral delivery systems, for an enterprise value of dkk 5.1 billion (approximately usd 820 million1). “as we build our pipeline of smoke-free products with the goal of phasing out cigarettes and expand our
PM Ratings Summary
PM Quant Ranking